Adenafil

Quick links to important sections

Adenafil

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adenafil

Property Description
Active ingredient Sildenafil
Form Film-coated tablet
Pharmacological class Selective PDE5 Inhibitor
General purpose Improvement of localized circulation
Origin Synthetic pharmaceutical

What Type of Medicine is Adenafil (Sildenafil)?

Adenafil is a synthetic pharmaceutical and is strictly categorized as a Prescription-Only Medicine (POM). It contains the active ingredient Sildenafil and is scientifically classified as a Selective Phosphodiesterase Type 5 (PDE5) Inhibitor. This classification places it within a specific class of cardiovascular agents engineered to manage conditions related to circulation. The drug is a single product (monotherapy), meaning its therapeutic action is derived entirely from the core substance, Sildenafil, whose profile is documented across medical literature.

Composition, Form, and Chemical Origin

The medication is composed of the active ingredient Sildenafil, typically administered as the salt form Sildenafil Citrate. This substance is produced entirely through chemical synthesis, confirming it as a synthetic compound. Adenafil is designed for oral administration and is manufactured primarily as a film-coated tablet, a form engineered for efficient delivery of the compound into the systemic circulation. This solid dosage form provides a standard method of administration.

General Therapeutic Focus and Purpose

The primary purpose of Adenafil is to act as a selective vasodilator, which is its intended role in managing conditions related to restrictive blood flow. By modulating a key physiological pathway, the medication facilitates smooth muscle relaxation and vessel dilation. This mechanism allows the drug to achieve and sustain the necessary state of improved localized circulation in specific tissues. This targeted action underscores its utility in scenarios where enhanced regional blood flow is medically required.

Regulatory References

  1. EMA Public Assessment Report for Sildenafil
  2. NIH MedlinePlus on Sildenafil
  3. Selective Phosphodiesterase Type 5 (PDE5) Inhibitor

What side effects are possible with Adenafil?

Possible side effects and safety information

The official safety profile for Adenafil, which contains the active ingredient Sildenafil, describes adverse reactions categorized by their frequency, based on regulatory documentation. Side effects are systematically grouped into System-Organ Classes (SOC) to identify the affected physiological systems.

Very Common reactions (expected in more than 1 in 10 patients) include Headache and Flushing (vasodilation). Common reactions (expected in less than 1 in 10 patients) include Dizziness, Visual disturbances (such as a color tinge to vision or blurred vision), Dyspepsia (indigestion), and Nasal congestion.

Serious and Rare Adverse Reactions

Serious adverse reactions, though Rare (expected in fewer than 1 in 1,000 patients), are documented in the regulatory label. These include Priapism (a prolonged erection lasting longer than four hours), sudden loss of vision (potentially Non-arteritic Anterior Ischemic Optic Neuropathy, or NAION), and sudden decrease or loss of hearing. Serious cardiovascular events, such as stroke or myocardial infarction, have also been reported in temporal association with use, primarily in individuals with pre-existing risk factors.

Safety Restrictions and Population Considerations

Use of this medicine is strictly contraindicated with any form of organic nitrate or nitric oxide donors due to the severe risk of hypotension. Contraindications also apply to individuals with a history of vision loss from NAION or a recent history of stroke or myocardial infarction. Specific regulatory warnings exist concerning chronic high-dose use in certain pediatric patients being treated for Pulmonary Arterial Hypertension and in patients with severe hepatic impairment, where use is prohibited by some regulatory bodies. Safety is officially listed as unknown in patients with active peptic ulceration or bleeding disorders.

Overdose and Emergency Response

The official regulatory documents for Adenafil (Sildenafil) define the overdose profile based on expected clinical manifestations and mandatory emergency actions. Overdose is formally documented as an increase in the rate and severity of adverse events seen at standard therapeutic doses. Documented physiological effects at higher exposure levels include decreased blood pressure (hypotension), syncope (fainting), and a prolonged erection.

Overdose Scope

Property Official Regulatory Statement
Documented Presentations Overdose may result in hypotension, syncope, and prolonged erection at higher exposures.
Population Notes Renal dialysis is not expected to enhance clearance. Higher drug exposure may occur in those with severe renal or hepatic impairment.

Emergency-Response and Management

The most critical regulatory instruction is to seek immediate medical assistance if an erection persists for longer than four hours. This action is mandatory due to the risk of irreversible penile tissue damage and potential permanent loss of potency. In all overdose scenarios, treatment should be symptomatic and supportive, as official regulatory text states that no specific antidote is known. This necessitates monitoring of vital signs and continuous clinical status assessment.

Therapeutic Uses of Adenafil

What Adenafil treats: Main Uses and Benefits

The primary therapeutic applications of the active ingredient in Adenafil (Sildenafil) are established for conditions related to impaired circulation in specific vascular beds. The medication is generally used to address two distinct clinical problems that result in significant symptomatic burden.

The medicine helps manage chronic conditions like Pulmonary Arterial Hypertension (PAH), a condition of the lung arteries, and is used for managing the core symptom of impaired erectile function in men. It is relevant in contexts where additional symptomatic support is needed, such as when symptoms create noticeable interference with functional stability or sexual health.

“This support assists men in managing symptoms that create noticeable interference with their sexual health and overall comfort.”

For patients with PAH, this medicine may generally help ease symptom clusters that may become intense or disruptive, such as shortness of breath and tiredness during physical activity. The primary benefit in this context may contribute to improved exercise ability and contributes to easing the overall symptom load for patients (including adults and children).

Quick Fact: Relief for Functional Limitations
Adenafil is applied in scenarios where symptoms create noticeable physiological strain by helping to address symptoms related to functional difficulty during sexual activity and by supporting general well-being during symptomatic phases in PAH.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Adenafil eligibility is strictly defined by regulatory authorities based on a patient's health status and age, ensuring use is limited to established populations.

Absolute Contraindications

Adenafil must not be used by patients taking any form of organic nitrate medicines (e.g., nitroglycerin) or soluble Guanylate Cyclase (sGC) stimulators. The medicine is also contraindicated in patients with a history of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION), severe hepatic impairment, resting hypotension, or a recent history of stroke or myocardial infarction within the last six months.

Age and Indication Eligibility

Use is approved for adults (18 years and older) for both approved indications. Pediatric use (age 1–17) is only permitted for the Pulmonary Arterial Hypertension (PAH) indication; it is not indicated for Erectile Dysfunction in those under 18.

Conditional Use and Restrictions

Use is restricted and requires caution in patients with severe renal impairment or mild to moderate hepatic impairment, where potential dose consideration is required. It is not recommended for patients with Pulmonary Veno-Occlusive Disease (PVOD) or for men advised against sexual activity due to cardiovascular risk. For pregnancy and lactation, adequate human studies are not established; clinical use requires a benefit-risk assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Contraindicated Combinations

Co-administration of Adenafil (Sildenafil) is contraindicated with any form of Organic Nitrate (regular or intermittent use) due to the substantial risk of potentiating hypotensive effects. Concomitant use with Riociguat, a soluble guanylate cyclase (sGC) stimulator, is also officially prohibited as it can lead to symptomatic hypotension, according to regulatory labeling.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substance/Category Official Restriction / Outcome
Exposure Alteration Potent CYP3A4 Inhibitors (e.g., Ritonavir) These agents increase Sildenafil plasma concentrations. The official restriction states the maximum single dose must not be exceeded within a 48-hour period.
Clearance Reduction Severe Renal or Hepatic Impairment Reduced drug clearance results in approximately double the exposure (AUC and C max) compared to healthy individuals.
Pharmacodynamic Alpha-blockers An additive blood pressure lowering effect is documented; Sildenafil should only be initiated once the patient is stable on alpha-blocker therapy.
Absorption Rate High-Fat Meal Reduces the rate of absorption, resulting in a documented delay in T max and a reduction in C max.

The interaction structure is defined by these regulatory requirements. CYP3A4-inducing agents, such as Rifampin, may reduce Sildenafil plasma levels. The label also advises against co-administration with other PDE5 inhibitors due to similar effects.

Mechanism of Action

Selective PDE5 Enzyme Inhibition

Adenafil's core action is the competitive inhibition of the Phosphodiesterase Type 5 ( PDE5) enzyme, an essential step that prevents the rapid breakdown of the intracellular messenger, cGMP. This molecular targeting is the basis of its molecular action, as it results in the natural relaxation signal being prolonged and potentiated.


Amplification of the NO - cGMP Signaling Pathway

The PDE5 blockade amplifies the body's natural Nitric Oxide ( NO) - cGMP signaling pathway. This sustained elevation of cGMP levels activates a cascade that reduces intracellular calcium concentration, a cellular signal triggering the altered state of smooth muscle tone. This mechanism is strictly dependent on the body's natural NO release.


Targeted Vascular Tone Modulation

The culmination of the molecular and cellular cascade is the alteration of vascular smooth muscle tone, leading to vasodilation (widening of the blood vessels) in specific PDE5-rich tissue beds. This peripheral action is a primary characteristic of the mechanism, as it produces the physiological consequence of increased localized blood flow.

Dosage and Administration Information

How to Use Adenafil: Administration Guidelines

This section outlines the standardized administration protocol for Adenafil.

Administration and Dosage

Scope Instruction
Administration Route Oral (PO) and Intravenous (IV) Infusion are the approved routes.
Dosing Schedule The regimen typically begins with an Initial Dose (X mg) followed by a Maintenance Dose of Z mg administered once daily. The Maximum Recommended Daily Dose must not be exceeded.
Frequency and Timing Administration is generally prescribed Once Daily (QD). Tablets should be taken with a full meal, while some formulations may require taking 1 hour before or 2 hours after food.

Preparation and Special Conditions

Oral tablets must be swallowed whole; instructions prohibit crushing or splitting unless the tablet is scored and specific instructions are provided. For the IV route, the injectable solution must be diluted with a specific fluid (e.g., Normal Saline or D5W) to the required concentration prior to infusion. IV administration is typically required to be performed slowly over a period of 60 minutes.

Patient-Specific Use and Protocol

Geriatric patients are instructed to begin treatment at the low end of the approved dosing range. Dose adjustments are mandatory for patients with documented renal impairment (Creatinine Clearance <30 mL/min) or specific classifications of hepatic impairment (e.g., Child-Pugh Class B or C). If a dose is missed, the patient should take it as soon as remembered, unless the next scheduled dose is imminent, in which case the missed dose must be skipped. Doubling the dose is prohibited.

Recent Clinical Evidence

Research evidence / Overview of studies for Adenafil

Evidence for Use in Impaired Erectile Function in Men

Research examined Adenafil for conditions characterized by functional limitations related to erectile function. These studies were primarily short-to-medium-term Randomized, Controlled Trials (RCTs) that compared the active compound to an inactive substance (placebo). The research monitored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, primarily using standardized questionnaires like the International Index of Erectile Function (IIEF) and patient-reported outcomes describing perceived discomfort.

The populations evaluated included a wide range of adult men. Studies observed that measurements on the validated functional scales were tracked in the research context for the active compound group compared to the placebo group. Trial participants generally reported how symptoms evolved in the observed populations, with some studies describing patterns related to outcomes describing episodic or acute changes. Evidence contributes to understanding symptom patterns across various subgroups.

Evidence for Use in Pulmonary Arterial Hypertension (PAH)

Adenafil was evaluated in adults and children (aged 1 to 17 years) with conditions involving periods of heightened symptoms, specifically Pulmonary Arterial Hypertension (PAH). The core research base consists of pivotal, intermediate-term RCTs which compared Adenafil against placebo. Studies explored outcomes linked to physiological strain or stress, primarily monitoring functional capacity using the six-minute walk distance (6MWD) test. Research also monitored outcomes related to systemic or functional imbalance, and research explored time until clinical worsening in both groups.

Studies examined functional capacity measures in the observed populations, where measurements of functional capacity (6MWD scores) were generally monitored for patients receiving the active compound. These findings describe patterns observed in the studies, and some meta-analyses suggest findings were similar when examining the results reported for both the adult and pediatric populations.

Long-Term Studies and Follow-up Durability

While initial research focused on short-term outcomes, some longer-term data is available, particularly for the PAH indication. For PAH, open-label extension studies monitored patients for several years after the initial trial. These studies data provided insight into functional status over the study period in the patients who continued treatment. For Impaired Erectile Function, the evidence from observational settings evaluating daily-life functioning over the long term remains more limited.

What is Still Uncertain About Adenafil Research

Research provides context but not individual predictions. One key limitation is that long-term outcomes are not fully established for many aspects across both indications, as follow-up durations were typically short-term in the definitive RCTs. For the PAH indication, sample sizes were modest in the initial trials, meaning results apply only to the populations studied and data for certain groups remain insufficient. While research has explored short-term symptom changes, there is limited information for long-term outcomes, such as data related to all-cause mortality, which was observed in some studies but requires more dedicated research.

Key Studies & References

  1. Sildenafil in the treatment of pulmonary hypertension (Review covering mechanism and clinical utility)
  2. Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension (Review on pediatric safety/uncertainty)

Frequently Asked Questions (FAQ)

Common questions about Adenafil (FAQ)


Q: How long does it typically take to feel the effects of Adenafil?

A: Official labeling advises that the medication may be taken approximately one hour prior to the intended use. Evidence indicates that the medication is effective between 30 minutes and 4 hours after administration. This timing can vary based on individual factors.


Q: What is the longest amount of time Adenafil stays in my system?

A: Data in the official pharmacokinetics section describes how the body processes the medication. Clinical studies indicate that the concentration of the active ingredient in the bloodstream is significantly reduced after 24 hours compared to its peak concentration. Data suggests that the systemic exposure is significantly reduced within that timeframe.


Q: What are the most commonly reported side effects people experience with Adenafil?

A: Based on official documentation, the most frequent adverse reactions reported in clinical trials are Headache and Flushing (a feeling of warmth). Other common effects include dizziness, visual disturbances like blurred vision, indigestion (dyspepsia), and nasal congestion.


Q: Does alcohol consumption change how Adenafil works?

A: Official consumer information advises caution regarding the consumption of alcohol while using the medication. This statement is typically made due to the potential for interactions with components that affect blood pressure.


Q: What is the purpose of the initial testing or screening before being able to use Adenafil?

A: The initial assessment is a standard procedure outlined in prescribing information. It is performed to identify whether a patient has pre-existing health issues, such as certain cardiovascular disorders, severe liver impairment, or recent cardiovascular events, which are listed as contraindications for use.


Q: Is there anything that can stop Adenafil from working properly?

A: Official prescribing information for the treatment of erectile dysfunction notes that the medication is only effective when accompanied by sexual stimulation. Additionally, regulatory documents state that taking the dose with a high-fat meal can slow down how quickly the medication is absorbed, potentially delaying the intended effect.


Q: Can Adenafil be taken by older adults or seniors?

A: The use of the medication in older adults is addressed in official documents. Official documents note that a lower starting dose is often described for patients in this demographic to account for potential differences in drug processing.


Q: Can Adenafil interact with herbal supplements or vitamins?

A: Official consumer information advises individuals to inform their healthcare professional about the use of all supplements, traditional medications, or herbal remedies. Separately, the FDA has warned consumers about fraudulent products marketed as 'herbal' that illegally contain the active ingredient.


Q: Are there different strengths or doses of Adenafil available?

A: The medication is manufactured in multiple tablet strengths, which are noted in official regulatory documents. These include strengths such as 25 mg, 50 mg, and 100 mg for one approved indication, and 20 mg tablets for the pulmonary arterial hypertension indication.


Q: Can women use Adenafil for any medical conditions?

A: Official labeling states that the medication is not indicated for the treatment of erectile dysfunction in female patients. For the Pulmonary Arterial Hypertension indication, its use in pregnant women requires a careful benefit-risk assessment due to insufficient human study data.


Q: What information is available about long-term use of Adenafil?

A: Official documentation, particularly for the Pulmonary Arterial Hypertension indication, includes data from open-label extension studies. These studies monitored the functional status of patients who continued treatment for several years, though comprehensive long-term outcome data is limited for all aspects and indications.


Q: Does Adenafil work for everyone who takes it?

A: Clinical research evidence indicates that in observed populations, the medication provided a measurable effect on symptom improvement. However, studies indicate that a percentage of study participants did not respond to the medication.


Q: Is Adenafil a medication that requires continuous use to maintain its effects?

A: The required protocol varies by the condition being addressed. For the Pulmonary Arterial Hypertension (PAH) indication, the official dosing schedule is typically prescribed as a maintenance dose administered multiple times a day. For the treatment of erectile dysfunction, the medication is taken only as needed.


Q: What is the difference between the generic and brand name versions of Adenafil?

A: Official documents classify the active ingredient as Sildenafil. Regulatory standards require generic versions to contain the same active ingredient and meet the same quality and performance standards (bioequivalence) as the original brand-name product. The main difference lies in the proprietary name and the manufacturer.


Q: How does official documentation describe the long-term effectiveness of Adenafil?

A: Official documentation reports that long-term functional status has been monitored in some open-label extension studies for the Pulmonary Arterial Hypertension indication. Evidence related to overall long-term outcomes for all indications remains limited.


Q: Can Adenafil be used with non-prescription cold or flu medicines?

A: Official labeling instructs patients to inform their healthcare professional about all new medicines they intend to take, including non-prescription products. This is advised due to the potential for interactions.


Q: Can using Adenafil affect future medical tests or procedures?

A: Regulatory safety information stresses the importance of informing healthcare providers about the use of this medication before certain procedures. This disclosure is relevant before receiving emergency medical care for a heart problem, as its use can impact decisions regarding the administration of other medicines.


Q: Why do some people say Adenafil didn't work for them?

A: Official clinical trial data indicates that the medication does not produce a measurable effect in all individuals who take it, showing a population non-response rate. For the treatment of erectile dysfunction, a lack of sexual stimulation is also noted in labeling as a factor that prevents the medication from working.

How should Adenafil be stored and disposed of?

Official Storage and Disposal Instructions

Adenafil (sildenafil) must be stored at room temperature and kept in the container it came in, tightly closed. Regulatory guidance mandates that the medication be protected from excess heat, moisture, and light to maintain its stability until the expiration date. It is essential to store the tablets out of the sight and reach of children.


Disposal Requirements

Expired or unused Adenafil should be handled according to local pharmaceutical waste regulations. The official disposal method is to use a drug take-back program. If a take-back program is unavailable, the medication must be mixed with an undesirable substance, such as dirt or used coffee grounds, and placed in a sealed container before discarding in the household trash. The labeling prohibits flushing the tablets down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Adenafil found in:

A-Z Index: